Last reviewed · How we verify
Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer
Approved treatments
- Datroway · Daiichi Sankyo
Deruxtecan works by binding to and inhibiting the growth of cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer patent landscape — cliff calendar, originator estates, attackable patents
- Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer treatment landscape brief
- Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer treatment updates RSS
Frequently asked questions about Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer
What drugs treat Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer?
Tracked treatments include Datroway.
What is the treatment for Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer?
Standard treatment for Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer includes Datroway. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer patent cliff · Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer CI report
- Treatment: Datroway · Daiichi Sankyo
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing